The Woodlands, Texas-based US Oncology Inc., an integrated oncology company, announced today that the San Rafael-based Association of Northern California Oncologists (ANCO) has selected Innovent Oncology as a preferred vendor for payer provider partnerships and front-end compliance models. ANCO says its role will be limited to informing, educating, and recommending that members proactively take advantage of front-end compliance programs such as Innovent Oncology to negotiate payer provider partnerships with major third-party payers. Innovent Oncology is a wholly-owned subsidiary of US Oncology designed by physicians and cancer care experts to expand patient access to high-quality, evidence-based medicine and proactive patient cancer care.
With a unique focus on supporting the entire care continuum for cancer patients, Innovent Oncology offers ANCO members a comprehensive, physician-driven cancer care solution that enhances the quality and consistency of patient care. ANCO physicians, working with Innovent Oncology, can access evidence-based treatment guidelines, proactive patient management services, and advance care planning to create value for patients. This collaborative program, coupled with managed care negotiations, aligns incentives to produce better outcomes and opportunities for enhanced reimbursement.
The foundation of Innovent Oncology's program is Level I Pathways, which are evidence-based guidelines used by hundreds of physicians in the United Network of US Oncology that offer ANCO physicians a more precise approach to cancer care compared to other generally accepted treatment guidelines. Developed by practicing community-based oncologists from the United Network of US Oncology, Level I Pathways assist physicians in making treatment decisions for the most commonly treated cancers and provide a consistent basis for delivering high-quality, evidence-based care. Pathways are documented through point-of-care decision support tools which provide a platform for standardization and outcomes measurement.